

ANI PHARMACEUTICALS INC
Form 8-K
February 03, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 29, 2015**

ANI PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

001-31812

(Commission File Number)

58-2301143

(I.R.S. Employer
Identification Number)

210 Main Street West

Baudette, Minnesota

56623

Edgar Filing: ANI PHARMACEUTICALS INC - Form 8-K

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: **(218) 634-3500**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

On January 29, 2015, Robert Jammick, Vice President, Quality and Product Development, retired.

Item 8.01 Other Events.

On February 3, 2015, ANI Pharmaceuticals, Inc. announced the promotion of David J. Sullivan, Ph.D. to the position of Vice President, Quality Operations.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit No. **Description**

99.1 Press release of ANI Pharmaceuticals, Inc., dated February 3, 2015

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANI
PHARMACEUTICALS, INC.**

By: /s/ Charlotte C.
Arnold
Charlotte C. Arnold
*Vice President, Finance
and Chief Financial
Officer*

Dated: February 3, 2015